Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 26 April 2012
Two life sciences giants are experiencing transitions in leadership, as AstraZeneca's Chief Executive Office David Brennan announced he was relinquishing his position effective immediately and incoming Johnson & Johnson (J&J) CEO Alex Gorsky assumes his position at the company on 26 April.
Rumors of Brennan's departure have been brewing for some time, but finally came to a head after the firm announced a 19% decrease in first-quarter profits, reports Reuters. The company has been grappling with the loss of patent exclusivity for many of its top-selling drugs, including blockbuster antipsychotic Seroquel.
Brennan will be replaced on an interim basis by Chief Financial Officer Simon Lowth, said The Associated Press.
For J&J, the arrival of Gorsky comes after a period of intense challenges. As Regulatory Focus reported in April, the company has been through an exhausting gauntlet of regulatory setbacks and scandals.
As The New York Times reports, Gorsky will now have to confront those challenges and look to rebuild not only the company's business, but it's reputation as well.
"I think we're going to need to be bold, disciplined and decisive about how we go forward," said Gorsky in an interview with The Times on 25 April.
Among the challenges identified by Gorsky: regulatory.
"I think the markets are going to demand a higher bar around innovation and really making a difference for patients," remarked Gorsky.
Read more:
PharmPro - AstraZeneca CEO to step down as Q1 profit plunges
Reuters - AstraZeneca CEO quits as profits tumble
Regulatory Focus - AstraZeneca Sues FDA to Halt Generic Seroquel
The New York Times - After Recalls and Missteps, J.&J.'s New Chief Confronts Critical Challenges
Regulatory Focus - J&J Earnings Drag as Regulatory Problems Accumulate
Read all Regulatory Focus Stories on Johnson & Johnson
Mass Device - New J&J CEO Gorsky wants to grow device business
Tags: CFO, AZ, Lowth, Brennan, Gorsky, Johnson, JNJ, CEO, Weldon, J&J, AstraZeneca, Latest News, head, leadership
Regulatory Focus newsletters
All the biggest regulatory news and happenings.